Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a hold rating to a strong-buy rating in a research report sent to investors on Saturday morning.

FMS has been the subject of several other research reports. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Thursday, May 15th. Truist Financial raised their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.7%

Shares of NYSE FMS opened at $28.12 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.46 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $17.93 and a 52 week high of $30.46. The firm has a 50-day moving average price of $27.98 and a 200 day moving average price of $25.19. The stock has a market capitalization of $16.50 billion, a price-to-earnings ratio of 25.11, a price-to-earnings-growth ratio of 0.66 and a beta of 0.87.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.18% and a return on equity of 6.25%. The firm had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $4.71 billion. Equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently announced an annual dividend, which was paid on Friday, June 6th. Shareholders of record on Friday, May 23rd were given a dividend of $0.7871 per share. The ex-dividend date was Friday, May 23rd. This represents a yield of 1.9%. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.44. Fresenius Medical Care AG & Co. KGaA’s payout ratio is presently 50.89%.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pzena Investment Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 0.6% during the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock worth $382,890,000 after acquiring an additional 94,065 shares during the last quarter. Millennium Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after acquiring an additional 361,364 shares during the last quarter. Integral Health Asset Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 33.3% during the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock worth $13,584,000 after acquiring an additional 150,000 shares during the last quarter. Todd Asset Management LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $12,009,000. Finally, Northern Trust Corp raised its position in Fresenius Medical Care AG & Co. KGaA by 5.0% during the first quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock worth $9,468,000 after acquiring an additional 18,061 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.